Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.

IF 2.3 Q3 CLINICAL NEUROLOGY

Neurodegenerative disease management Pub Date : 2022-04-01 Epub Date: 2021-12-21 DOI:10.2217/nmt-2021-0031

Tjalf Ziemssen, Anna Kurzeja, Bogdan Muresan, Jennifer S Haas, Jessica Alexander, Maurice T Driessen

{"title":"Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.","authors":"Tjalf Ziemssen, Anna Kurzeja, Bogdan Muresan, Jennifer S Haas, Jessica Alexander, Maurice T Driessen","doi":"10.2217/nmt-2021-0031","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate adherence, healthcare resource utilization (HRU) and costs for glatiramer acetate (GA; injectable), dimethyl fumarate (oral) and teriflunomide (oral) in relapsing multiple sclerosis. Patients & methods: Retrospective analyses of a claims database. Results: Teriflunomide patients were older with more co-morbidities and fewer relapses versus GA and dimethyl fumarate. GA patients were mostly disease-modifying therapies (DMTs)-treatment naive. Treatment adherence was 61-70%. All DMTs reduced HRU versus pre-index. Costs were comparable across cohorts. High adherence reduced hospitalizations and several costs versus low adherers. Conclusion: Adherence rates were high and comparable with all DMTs. Similar (and high) reductions in HRU and costs occurred with all DMTs. High adherence improved economic outcomes versus low adherence. Thus, investing in adherence improvement is beneficial to improve outcomes in relapsing multiple sclerosis.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"12 2","pages":"93-107"},"PeriodicalIF":2.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2021-0031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: To evaluate adherence, healthcare resource utilization (HRU) and costs for glatiramer acetate (GA; injectable), dimethyl fumarate (oral) and teriflunomide (oral) in relapsing multiple sclerosis. Patients & methods: Retrospective analyses of a claims database. Results: Teriflunomide patients were older with more co-morbidities and fewer relapses versus GA and dimethyl fumarate. GA patients were mostly disease-modifying therapies (DMTs)-treatment naive. Treatment adherence was 61-70%. All DMTs reduced HRU versus pre-index. Costs were comparable across cohorts. High adherence reduced hospitalizations and several costs versus low adherers. Conclusion: Adherence rates were high and comparable with all DMTs. Similar (and high) reductions in HRU and costs occurred with all DMTs. High adherence improved economic outcomes versus low adherence. Thus, investing in adherence improvement is beneficial to improve outcomes in relapsing multiple sclerosis.

查看原文本刊更多论文

在德国使用醋酸格拉替默、富马酸二甲酯或特立氟米特治疗的多发性硬化症复发患者的真实世界患者特征、治疗模式和成本

目的:评价醋酸格拉替默(GA)的依从性、医疗资源利用率(HRU)和成本;可注射)，富马酸二甲酯(口服)和特立氟米特(口服)复发多发性硬化症。患者与方法:回顾性分析索赔数据库。结果:与GA和富马酸二甲酯相比，特立氟米特患者年龄更大，合并症更多，复发更少。GA患者大多采用疾病修饰疗法(dmt)-初始治疗。治疗依从性为61-70%。与索引前相比，所有dmt均降低了HRU。不同队列的成本具有可比性。与低依从者相比，高依从性降低了住院率和多项费用。结论:依从率高，与所有dmt相当。在所有的dmt中，HRU和成本都出现了类似的(并且很高的)降低。与低依从性相比，高依从性改善了经济结果。因此，投资于依从性改善有利于改善复发性多发性硬化症的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurodegenerative disease management CLINICAL NEUROLOGY-

CiteScore

4.30

自引率

0.00%

发文量